Mirum Pharmaceuticals, Inc. MIRM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s stock-based comp?
- Mirum Pharmaceuticals, Inc. (MIRM) reported stock-based comp of $36.2M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s stock-based comp increased by 129.1% year-over-year, from $15.8M to $36.2M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s stock-based comp has grown at a 32.6% compound annual growth rate (CAGR), from $23.09M to $71.42M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.